Novavax’s updated XBB.1.5 vaccine shows promising cross-neutralizing antibodies against new COVID-19 variants

The study reveals that Novavax’s updated XBB.1.5 vaccine effectively induces cross-neutralizing antibodies against multiple Omicron XBB sub-variants in both mice and non-human primates.

Commure to Acquire Augmedix in $139M All-Cash Deal – M&A

What You Should Know: – Augmedix (AUGX), a leader in AI-powered medical documentation and data solutions, is being acquired by healthcare technology provider Commure in

July 19, 2024

Jiangsu Hengrui, a preferred China partner for U.S. biotech, hints at more deals

SAN FRANCISCO — One of the U.S. biotech industry’s preferred partners in China, Jiangsu Hengrui Pharmaceuticals, emphasized its global ambitions and plans for more dealmaking at

January 16, 2025

Researchers uncover immune system barrier to cancer treatment

By recruiting the immune system to combat tumor cells, immunotherapy has improved survival rates, offering hope to millions of cancer patients. However, only about one

August 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.